FDA Press Announcements published a current U.S. medical or healthcare update on October 19, 2026. The story is receiving priority because the agent rated it as a timely, high-impact topic in public health and disease prevention. This article summarizes the verified source material and separates confirmed facts from issues that still need to be watched.
What happened?
The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.
Key facts from the source
- Completing this review nearly 4 months ahead of schedule means some patients who might otherwise be preparing for surgery, radiation or chemotherapy may now have a different conversation with their doctor.” Today’s approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer.
- Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.
- For certain types of rectal cancer, this approval represents a groundbreaking option that avoids surgery, radiation and chemotherapy.
- Patients with locally advanced rectal cancer often receive chemotherapy and radiation prior to surgery, which can affect bowel, urinary, and sexual function, as well as fertility.
- The FDA granted Priority Review to the application and Breakthrough Therapy designation to Jemperli for the treatment of dMMR or MSI-H locally advanced rectal cancer.
Why this matters in U.S. healthcare
Public-health alerts can quickly affect prevention, testing, vaccination, infection control, and communication with patients. Fast-moving outbreaks or safety warnings deserve close attention because recommendations may change as new data emerge.
Who may be affected?
Patients, clinicians, public-health departments, pharmacies, laboratories, schools, employers, or healthcare facilities may be affected depending on the event.
What to watch next
- Monitor CDC and state/local health-department updates.
- Watch for case-count, geographic, or exposure updates.
- Check whether testing, vaccination, prevention, or treatment guidance changes.
- Use the latest official guidance for patient-facing decisions.
Key takeaway
This is a developing medical-news item selected for recency, U.S. relevance, potential impact, source quality, and independent coverage where available. The original source remains the authority for exact clinical, regulatory, safety, coverage, or policy details.
Frequently asked questions
Is this article medical advice?
No. It is a news summary based on cited public sources and is not a substitute for clinical guidance or patient-specific medical advice.
How current is this story?
The agent prioritizes articles published within its configured hot-news window and rejects older stories from automatic publication.
How is a topic selected?
Stories are ranked using freshness, U.S. relevance, potential healthcare impact, source authority, and corroboration across separate sources.
Sources
Primary source: FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery — FDA Press Announcements.